Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Ascendis Pharma (Nasdaq: ASND) reported Week 104 data from the pivotal ApproaCH trial of once-weekly TransCon CNP in 84 children with achondroplasia. Radiographic assessments showed continued improvements in tibial-femoral angle (TFA) and TFA Z-scores through two years, greater in children with preexisting genu varum, with stable fibula-to-tibia ratios and a generally well-tolerated safety profile.
Ascendis (Nasdaq: ASND) has been added to multiple Russell U.S. indexes, including the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap, effective after the U.S. market close on June 26, 2026.
These indexes cover most investable U.S. equities and serve as key benchmarks, with about $11.8 trillion in assets benchmarked to Russell U.S. Indexes as of December 31, 2024.
Ascendis (Nasdaq: ASND) will present new clinical data in achondroplasia at ICCBH 2026 in Montreal, June 27-30. Presentations cover Week 104 lower-extremity alignment results from the pivotal ApproaCH Trial of TransCon CNP and 52-week Phase 2 COACH Trial combination data with TransCon CNP and TransCon hGH.
TransCon CNP, approved by the FDA as YUVIWEL in February 2026, is under EMA review for children with achondroplasia. TransCon hGH (SKYTROFA) is approved for growth hormone deficiency and remains investigational in achondroplasia.
Ascendis Pharma (Nasdaq: ASND) reported Week 182 Phase 3 PaTHway data showing long-term TransCon PTH (palopegteriparatide) treatment sustained efficacy and safety in adults with hypoparathyroidism.
86% met a multi-component endpoint, 89% completed the 3.5-year trial, kidney function and quality-of-life measures improved and remained stable, and no anti-PTH antibodies emerged.
Ascendis Pharma (Nasdaq: ASND) reported 5-year Phase 2 PaTH Forward data showing TransCon PTH (palopegteriparatide) maintained normalized calcium, improved kidney function, and supported quality of life in adults with hypoparathyroidism.
At Week 266, 82% met the multi-component response, 95% completed treatment, and safety remained generally well-tolerated.
Ascendis (Nasdaq: ASND) will present new data from its rare endocrine disease programs at ENDO 2026 in Chicago, June 13–16, 2026.
Presentations cover hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency, including Phase 3 PaTHway and Phase 2 COACH trial results and registry data on lonapegsomatropin.
Ascendis Pharma (Nasdaq: ASND) reported Q1 2026 results: total revenue €247m, driven by YORVIPATH €197m and SKYTROFA €44m. The company received FDA accelerated approval and orphan exclusivity for YUVIWEL and agreed to sell a Rare Pediatric Disease PRV for $187.5m. Q1 net profit was €629m including recognition of €679m deferred tax assets; non-IFRS net profit was €18m. Cash and cash equivalents were €573m as of March 31, 2026.
Ascendis Pharma (Nasdaq: ASND) reported 2-year subgroup data from the pivotal ApproaCH trial showing children with achondroplasia aged ≥5 at enrollment treated with once-weekly TransCon CNP (navepegritide) had greater annualized growth velocity (AGV) versus placebo at Week 52 and sustained growth through Week 104.
Key metrics: Week 52 AGV treatment difference +1.78 cm/year (LS mean, 95% CI [1.22,2.33]); ACH-specific height Z-score change +0.31 vs placebo. Safety through two years showed low, mild injection-site reactions, no symptomatic hypotension, and no bone-age acceleration.
Ascendis Pharma (Nasdaq: ASND) will report first quarter 2026 financial results and provide a business update on May 7, 2026, before U.S. market open. The company will host a conference call and live webcast on May 7, 2026 at 8:00 a.m. ET.
Registration links and a live-webcast link will be available via the Investors & News section of the Ascendis Pharma website. A replay will be posted and available for 30 days after the event.
Ascendis Pharma (Nasdaq: ASND) called for redemption of all $575.0 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2028, with a redemption date of May 6, 2026.
Holders may convert through 5:00 p.m. NY on May 4, 2026; conversion rate is 6.0118 shares per $1,000, increased to 6.3232 shares during the Make-Whole Conversion Period, making up to 3,635,840 ordinary shares issuable if converted.